Boughton B J, Sheehan T M, Wood J, O'Brien D, Butler M, Simpson A, Hale K A
Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
Ann Clin Biochem. 1995 Jan;32 ( Pt 1):79-83. doi: 10.1177/000456329503200108.
Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy. To examine the value of monitoring plasma concentrations of the drug in such patients, we have developed a high-performance liquid chromatographic (HPLC) assay. The method uses 0.5 mL plasma, is linear to 10 mg/L and had a detection limit of 0.2 mg/L. Thalidomide in plasma specimens was unstable at physiological pH but could be stabilized for several weeks by simple acidification. We describe a protocol for monitoring patients treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects.
沙利度胺目前被广泛用于治疗慢性移植物抗宿主病，但其使用与诸如周围神经病变等非致畸性副作用相关。为了研究监测此类患者血浆药物浓度的价值，我们开发了一种高效液相色谱（HPLC）测定法。该方法使用0.5 mL血浆，线性范围为10 mg/L，检测限为0.2 mg/L。血浆标本中的沙利度胺在生理pH值下不稳定，但通过简单酸化可稳定数周。我们描述了一种监测沙利度胺治疗患者的方案，该方案允许标本的便捷运输和储存，并初步报告，血浆浓度在1-7 mg/L范围内对慢性移植物抗宿主病具有治疗效果且无不良副作用。
